APA

Harbeck N., Alt U., Berger U., Krüger A., Thomssen C., Jänicke F., Höfler H., Kates R. E. & Schmitt M. (20011004). Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy. : Clinical cancer research : an official journal of the American Association for Cancer Research.

Chicago

Harbeck N, Alt U, Berger U, Krüger A, Thomssen C, Jänicke F, Höfler H, Kates R E and Schmitt M. 20011004. Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy. : Clinical cancer research : an official journal of the American Association for Cancer Research.

Harvard

Harbeck N., Alt U., Berger U., Krüger A., Thomssen C., Jänicke F., Höfler H., Kates R. E. and Schmitt M. (20011004). Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy. : Clinical cancer research : an official journal of the American Association for Cancer Research.

MLA

Harbeck N, Alt U, Berger U, Krüger A, Thomssen C, Jänicke F, Höfler H, Kates R E and Schmitt M. Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy. : Clinical cancer research : an official journal of the American Association for Cancer Research. 20011004.